JPH08511936A - 多発性硬化症ウィルス - Google Patents

多発性硬化症ウィルス

Info

Publication number: JPH08511936A
Authority: JP; Japan
Prior art keywords: hmsv; genome; polypeptide; antibody; sequence
Prior art date: 1993-05-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP7500386A

Other languages

English (en)

Japanese (ja)

Other versions

JPWO1993024121A1 (ja

Inventor

ジェレミーガーソン

フィリップトゥーク

Original Assignee

ユニヴァーシティカレッジロンドン

ビオムリュエスアー

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-05-24

Filing date

1994-05-24

Publication date

1996-12-17

1994-05-24 Application filed by ユニヴァーシティカレッジロンドン, ビオムリュエスアー filed Critical ユニヴァーシティカレッジロンドン

1994-06-02 Publication of JPWO1993024121A1 publication Critical patent/JPWO1993024121A1/ja

1996-12-17 Publication of JPH08511936A publication Critical patent/JPH08511936A/ja

Status Pending legal-status Critical Current

Links

201000006417 multiple sclerosis Diseases 0.000 title claims abstract description 34
241000700605 Viruses Species 0.000 title claims abstract description 28
108091033319 polynucleotide Proteins 0.000 claims abstract description 53
102000040430 polynucleotide Human genes 0.000 claims abstract description 53
239000002157 polynucleotide Substances 0.000 claims abstract description 53
239000002773 nucleotide Substances 0.000 claims abstract description 27
125000003729 nucleotide group Chemical group 0.000 claims abstract description 27
108700026244 Open Reading Frames Proteins 0.000 claims abstract description 18
108090000623 proteins and genes Proteins 0.000 claims abstract description 14
102000004169 proteins and genes Human genes 0.000 claims abstract description 13
108091032973 (ribonucleotides)n+m Proteins 0.000 claims abstract description 12
108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 11
102000040650 (ribonucleotides)n+m Human genes 0.000 claims abstract description 8
102100034343 Integrase Human genes 0.000 claims abstract description 8
108010076039 Polyproteins Proteins 0.000 claims abstract description 8
108010092799 RNA-directed DNA polymerase Proteins 0.000 claims abstract description 8
230000000295 complement effect Effects 0.000 claims abstract description 8
108090000765 processed proteins & peptides Proteins 0.000 claims description 82
102000004196 processed proteins & peptides Human genes 0.000 claims description 76
229920001184 polypeptide Polymers 0.000 claims description 73
238000000034 method Methods 0.000 claims description 35
239000000523 sample Substances 0.000 claims description 35
239000000427 antigen Substances 0.000 claims description 24
150000007523 nucleic acids Chemical class 0.000 claims description 18
102000039446 nucleic acids Human genes 0.000 claims description 15
108020004707 nucleic acids Proteins 0.000 claims description 15
150000001413 amino acids Chemical class 0.000 claims description 14
108091007433 antigens Proteins 0.000 claims description 13
102000036639 antigens Human genes 0.000 claims description 13
230000000890 antigenic effect Effects 0.000 claims description 12
239000013598 vector Substances 0.000 claims description 11
239000000203 mixture Substances 0.000 claims description 10
241000894007 species Species 0.000 claims description 8
230000003612 virological effect Effects 0.000 claims description 8
238000003752 polymerase chain reaction Methods 0.000 claims description 7
238000003018 immunoassay Methods 0.000 claims description 6
239000007787 solid Substances 0.000 claims description 5
239000013604 expression vector Substances 0.000 claims description 4
239000012472 biological sample Substances 0.000 claims description 2
239000000126 substance Substances 0.000 claims description 2
150000002632 lipids Chemical class 0.000 claims 1
210000004027 cell Anatomy 0.000 description 29
108020004414 DNA Proteins 0.000 description 13
235000001014 amino acid Nutrition 0.000 description 13
239000002299 complementary DNA Substances 0.000 description 12
235000018102 proteins Nutrition 0.000 description 10
239000012634 fragment Substances 0.000 description 9
238000011282 treatment Methods 0.000 description 9
125000003275 alpha amino acid group Chemical group 0.000 description 8
230000027455 binding Effects 0.000 description 8
108091026890 Coding region Proteins 0.000 description 7
239000002245 particle Substances 0.000 description 6
201000010099 disease Diseases 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
239000003814 drug Substances 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
241001430294 unidentified retrovirus Species 0.000 description 5
241000725303 Human immunodeficiency virus Species 0.000 description 4
230000002068 genetic effect Effects 0.000 description 4
230000001900 immune effect Effects 0.000 description 4
230000002163 immunogen Effects 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 3
238000003745 diagnosis Methods 0.000 description 3
238000009396 hybridization Methods 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
238000002955 isolation Methods 0.000 description 3
239000000463 material Substances 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
229960005486 vaccine Drugs 0.000 description 3
241000894006 Bacteria Species 0.000 description 2
108700010070 Codon Usage Proteins 0.000 description 2
102000053602 DNA Human genes 0.000 description 2
241000206602 Eukaryota Species 0.000 description 2
206010035226 Plasma cell myeloma Diseases 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
230000021736 acetylation Effects 0.000 description 2
238000006640 acetylation reaction Methods 0.000 description 2
239000003443 antiviral agent Substances 0.000 description 2
230000002238 attenuated effect Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
238000010367 cloning Methods 0.000 description 2
230000002950 deficient Effects 0.000 description 2
238000013461 design Methods 0.000 description 2
238000002405 diagnostic procedure Methods 0.000 description 2
238000009826 distribution Methods 0.000 description 2
241001493065 dsRNA viruses Species 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
230000002452 interceptive effect Effects 0.000 description 2
235000018977 lysine Nutrition 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
230000035772 mutation Effects 0.000 description 2
201000000050 myeloid neoplasm Diseases 0.000 description 2
210000002569 neuron Anatomy 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
238000011321 prophylaxis Methods 0.000 description 2
230000009257 reactivity Effects 0.000 description 2
230000010076 replication Effects 0.000 description 2
238000012216 screening Methods 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
238000013519 translation Methods 0.000 description 2
241000004176 Alphacoronavirus Species 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
241000714198 Caliciviridae Species 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
239000003298 DNA probe Substances 0.000 description 1
230000004543 DNA replication Effects 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
241000709664 Picornaviridae Species 0.000 description 1
241000712907 Retroviridae Species 0.000 description 1
108091028664 Ribonucleotide Proteins 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
241000555745 Sciuridae Species 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
108091081024 Start codon Proteins 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000000556 agonist Substances 0.000 description 1
230000004075 alteration Effects 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
238000003491 array Methods 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000012258 culturing Methods 0.000 description 1
239000005547 deoxyribonucleotide Substances 0.000 description 1
125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000000032 diagnostic agent Substances 0.000 description 1
229940039227 diagnostic agent Drugs 0.000 description 1
231100000676 disease causative agent Toxicity 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
210000000416 exudates and transudate Anatomy 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000004927 fusion Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
125000003147 glycosyl group Chemical group 0.000 description 1
230000035931 haemagglutination Effects 0.000 description 1
230000028996 humoral immune response Effects 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
210000001822 immobilized cell Anatomy 0.000 description 1
230000000984 immunochemical effect Effects 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
150000002669 lysines Chemical class 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
244000005700 microbiome Species 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
239000008267 milk Substances 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000007659 motor function Effects 0.000 description 1
210000003007 myelin sheath Anatomy 0.000 description 1
210000004498 neuroglial cell Anatomy 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
238000007899 nucleic acid hybridization Methods 0.000 description 1
238000002515 oligonucleotide synthesis Methods 0.000 description 1
108010091748 peptide A Proteins 0.000 description 1
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
108700004029 pol Genes Proteins 0.000 description 1
101150088264 pol gene Proteins 0.000 description 1
230000002265 prevention Effects 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
239000002994 raw material Substances 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
239000002336 ribonucleotide Substances 0.000 description 1
125000002652 ribonucleotide group Chemical group 0.000 description 1
102220201851 rs143406017 Human genes 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
230000037152 sensory function Effects 0.000 description 1
239000000758 substrate Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
210000001138 tear Anatomy 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
238000010361 transduction Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000014621 translational initiation Effects 0.000 description 1
238000002424 x-ray crystallography Methods 0.000 description 1
JLYXXMFPNIAWKQ-UHFFFAOYSA-N γ Benzene hexachloride Chemical compound ClC1C(Cl)C(Cl)C(Cl)C(Cl)C1Cl JLYXXMFPNIAWKQ-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Virology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Saccharide Compounds (AREA)

JP7500386A 1993-05-24 1994-05-24 多発性硬化症ウィルス Pending JPH08511936A (ja)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
JP4-130828		1992-05-22
GB939310657A GB9310657D0 (en)	1993-05-24	1993-05-24	Retrovirus
GB9310657.3		1993-05-24
PCT/GB1994/001129 WO1994028138A1 (en)	1993-05-24	1994-05-24	Multiple sclerosis virus

Publications (2)

Publication Number	Publication Date
JPWO1993024121A1 JPWO1993024121A1 (ja)	1994-06-02
JPH08511936A true JPH08511936A (ja)	1996-12-17

Family

ID=10736021

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP7500386A Pending JPH08511936A (ja)	1993-05-24	1994-05-24	多発性硬化症ウィルス

Country Status (10)

Country	Link
US (1)	US6136528A (de)
EP (1)	EP0700441B1 (de)
JP (1)	JPH08511936A (de)
AT (1)	ATE274584T1 (de)
AU (1)	AU676568B2 (de)
CA (1)	CA2163641C (de)
DE (1)	DE69433964T2 (de)
ES (1)	ES2227525T3 (de)
GB (1)	GB9310657D0 (de)
WO (1)	WO1994028138A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2727428B1 (fr) *	1994-11-24	1997-04-30	Bio Merieux	Virus msrv1 associe a la sclerose en plaques et ses constituants nucleiques
FR2715937A1 (fr) *	1994-02-04	1995-08-11	Bio Merieux	Virus MSRV1 et MSRV2 associés ensemble à la sclérose en plaques et leurs constituants nucléiques.
FR2728585A1 (fr) *	1994-12-23	1996-06-28	Bio Merieux	Virus msrv1 et agent pathogene et/ou infectant msrv2 associes a la sclerose en plaques et leurs constituants nucleiques
FR2689520B1 (fr) *	1992-04-03	1996-07-19	Bio Merieux	Procede et milieu de culture pour l'obtention de cellules infectees par un virus associe a la sclerose en plaques.
FR2689521B1 (fr) *	1992-04-03	1996-07-19	Bio Merieux	Procede d'obtention et maintien d'une culture cellulaire viable, infectee par un virus associe a la sclerose en plaques, et produits biologiques derives de ladite culture.
NZ279855A (en) *	1994-02-04	1998-05-27	Bio Merieux	Msrv1 and msrv2 pathogenic and/or infectious agents associated with ms, nucleic acids encoding them and diagnostic and therapeutic applications
FR2716198B1 (fr) *	1994-02-15	1996-04-19	Bio Merieux	Facteur cytotoxique tel qu'associé à la sclérose en plaques, sa détection et sa quantification.
FR2731356B1 (fr) *	1995-03-09	1997-04-30	Bio Merieux	Virus msrv-1 et agent pathogene et/ou infectant msrv-2 associes a la polyarthrite rhumatoide
FR2737500B1 (fr)	1995-08-03	1997-08-29	Bio Merieux	Materiel viral et fragments nucleotidiques associes a la sclerose en plaques, a des fins de diagnostic, prophylactiques et therapeutiques
WO1998023755A1 (en) *	1996-11-26	1998-06-04	Bio Merieux	Viral material and nucleotide fragments associated with multiple sclerosis, for diagnostic, prophylactic and therapeutic purposes
FR2765588A1 (fr)	1997-07-07	1999-01-08	Bio Merieux	Materiel nucleique retroviral et fragments nucleotidiques notamment associes a la sclerose en plaques et/ou la polyarthrite rhumatoide, a des fins de diagnostic, prophylactiques et therapeutiques
JP2002511277A (ja) *	1998-04-08	2002-04-16	エムエス・リサーチ・アクティーゼルスカブ	多発性硬化症および他の脱髄性疾患の診断
FR2788784A1 (fr)	1999-01-21	2000-07-28	Bio Merieux	Fragment nucleique endogene associe a une maladie auto-immune, procede de marquage et reactif
EP1029917A1 (de) *	1999-02-15	2000-08-23	Bio Merieux	Die LTR-Region von MSRV und die durch sie kodierten Proteine, und Sonden und Methoden für Detektion des MSRV-1 Retrovirus
FR2791140B1 (fr) *	1999-03-19	2002-03-22	Bio Merieux	Procede de detection d'une activite superantigenique dans un echantillon et composition therapeutique ou prophylactique

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ218050A (en) *	1985-11-13	1989-05-29	Wistar Inst	Test for the presence of htlv-1v
CA2095539A1 (en) *	1990-11-14	1992-05-15	Robert D. Cook	Diagnosis and treatment of multiple sclerosis

1993
- 1993-05-24 GB GB939310657A patent/GB9310657D0/en active Pending
1994
- 1994-05-24 EP EP94915674A patent/EP0700441B1/de not_active Expired - Lifetime
- 1994-05-24 US US08/553,411 patent/US6136528A/en not_active Expired - Fee Related
- 1994-05-24 AU AU67600/94A patent/AU676568B2/en not_active Ceased
- 1994-05-24 AT AT94915674T patent/ATE274584T1/de not_active IP Right Cessation
- 1994-05-24 CA CA002163641A patent/CA2163641C/en not_active Expired - Fee Related
- 1994-05-24 WO PCT/GB1994/001129 patent/WO1994028138A1/en not_active Ceased
- 1994-05-24 JP JP7500386A patent/JPH08511936A/ja active Pending
- 1994-05-24 DE DE69433964T patent/DE69433964T2/de not_active Expired - Fee Related
- 1994-05-24 ES ES94915674T patent/ES2227525T3/es not_active Expired - Lifetime

Also Published As

Publication number	Publication date
AU676568B2 (en)	1997-03-13
GB9310657D0 (en)	1993-07-07
AU6760094A (en)	1994-12-20
CA2163641A1 (en)	1994-12-08
WO1994028138A1 (en)	1994-12-08
ES2227525T3 (es)	2005-04-01
US6136528A (en)	2000-10-24
DE69433964T2 (de)	2005-09-08
EP0700441B1 (de)	2004-08-25
CA2163641C (en)	2003-12-30
EP0700441A1 (de)	1996-03-13
ATE274584T1 (de)	2004-09-15
DE69433964D1 (de)	2004-09-30

Publication	Publication Date	Title
RU2235131C2 (ru)	2004-08-27	Моноклональное антитело, нуклеиновая кислота и вектор, кодирующие антитело, и использование антитела для диагностики и лечения злокачественных заболеваний
US6417324B1 (en)	2002-07-09	Synthetic peptides that bind to the hepatitis B virus core and e antigens
RU2275379C2 (ru)	2006-04-27	Способы и композиции для ингибирования размножения вич-1
KR19990077146A (ko)	1999-10-25	유방암의 치료 및 진단용 조성물 및 방법
JPH08511936A (ja)	1996-12-17	多発性硬化症ウィルス
KR20010012813A (ko)	2001-02-26	결핵 확인용 화합물 및 이의 사용 방법
UA73475C2 (en)	2005-08-15	Hepatitis b virus strain, induced by vaccine, nucleic acid isolated molecule coding mutant main surface antiigen of hepatitis b virus, vector and vector system for the preparation of polypeptide, a method for the preparation of polypeptide (variants), purified polypeptide (variants), oligonucleotide, a method for the preparation of antibodies (variants), antibody (variants), a method for the determination of chemical compound for treating the infection of hepatitis b strain infection, a composition, a method for the preparation of composition, a method of organism liquids screening for hepatitis b virus, a method of antibody use, vaccine against hepatitis
JP2003523188A (ja)	2003-08-05	Ａｉｄｓ先祖ウイルスおよびワクチン
US6855323B2 (en)	2005-02-15	Identification of the domain of Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) that mediates adhesion to chondroitin sulfate A
JP2007500518A (ja)	2007-01-18	祖先ウィルスおよびワクチン
JP2002515249A (ja)	2002-05-28	Ｈｃｖのｅ２糖タンパク質の超可変部１のミモトープおよびその使用
JP2726264B2 (ja)	1998-03-11	Ｎ‐ｍｙｃタンパク質のためのアッセイ及び抗体
US20040234542A1 (en)	2004-11-25	Recombinant orf2 proteins of the swine hepatitis e virus and their use as a vaccine and as a diagnostic reagent for medical and veterinary applications
AU756866B2 (en)	2003-01-23	A mutant human hepatitis B viral strain and uses thereof
JPWO2003037917A1 (ja)	2005-02-17	腫瘍抗原
JP3455782B2 (ja)	2003-10-14	強皮症の診断薬
WO2011030300A1 (en)	2011-03-17	Synthetic peptides from the sv40 t-antigen for use in an indirect elisa test for the identification of antibodies against simian virus 40 in human serum and other fluids
JP3756974B2 (ja)	2006-03-22	ジェノタイプ１ｂのＣ型肝炎ウイルスに対する治療の有効性の判定方法
US6620913B1 (en)	2003-09-16	Polypeptides of a novel hantavirus
US8332159B2 (en)	2012-12-11	Method for enhancing efficacy of preparation of monoclonal antibody
OSLAND et al.	1996	Identification and characterization of human B‐cell epitopes in recombinant antigens of Leishmania aethiopica
CN119241666A (zh)	2025-01-03	乙型肝炎病毒的胸腺依赖性淋巴细胞抗原表位肽及其应用
US20040057961A1 (en)	2004-03-25	Human t cell response to mhc-binding motif clusters
EP1536013A1 (de)	2005-06-01	Zur hepatitisdiagnose geeignete dna-sequenz und dadurch codiertes polypeptid
CA2324441A1 (en)	1999-10-07	Materials and methods relating to a novel retrovirus